NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis

  • Vangelis Kondylis
  • Apostolos Polykratis
  • Hanno Ehlken
  • Laura Ochoa-Callejero
  • Beate Katharina Straub
  • Santosh Krishna-Subramanian
  • Trieu-My Van
  • Harald-Morten Curth
  • Nicole Heise
  • Falk Weih
  • Ulf Klein
  • Peter Schirmacher
  • Michelle Kelliher
  • Manolis Pasparakis

Abstract

IκB kinase/nuclear factor κB (IKK/NF-κB) signaling exhibits important yet opposing functions in hepatocarcinogenesis. Mice lacking NEMO in liver parenchymal cells (LPC) spontaneously develop steatohepatitis and hepatocellular carcinoma (HCC) suggesting that NF-κB prevents liver disease and cancer. Here, we show that complete NF-κB inhibition by combined LPC-specific ablation of RelA, c-Rel, and RelB did not phenocopy NEMO deficiency, but constitutively active IKK2-mediated NF-κB activation prevented hepatocellular damage and HCC in NEMO(LPC-KO) mice. Knock-in expression of kinase inactive receptor-interacting protein kinase 1 (RIPK1) prevented hepatocyte apoptosis and HCC, while RIPK1 ablation induced TNFR1-associated death domain protein (TRADD)-dependent hepatocyte apoptosis and liver tumors in NEMO(LPC-KO) mice, revealing distinct kinase-dependent and scaffolding functions of RIPK1. Collectively, these results show that NEMO prevents hepatocarcinogenesis by inhibiting RIPK1 kinase activity-driven hepatocyte apoptosis through NF-κB-dependent and -independent functions.

Bibliografische Daten

OriginalspracheEnglisch
ISSN1535-6108
DOIs
StatusVeröffentlicht - 09.11.2015
Extern publiziertJa
PubMed 26555174